Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 14, 2019. The document serves as a transaction notification regarding a specific equity award to a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure of a single share transaction.
| Metric | Value |
|---|---|
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Type | Award under the 2009 Share Value Plan |
| Volume | 3,020 shares |
| Price per Share | £15.47 |
| Transaction Date | February 13, 2019 |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely documents an initial notification of a share award to Mrs. V A Whyte, SVP & Company Secretary.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a standard compliance report for insider trading disclosures.
Key Facts for Investor Verification
- The transaction involved an award of 3,020 ordinary shares to a senior executive.
- The transaction price was £15.47 per share, executed on February 13, 2019.
- This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F for comprehensive financial data.